Abstract
Twenty-two patients suspected for primary or recurrent ovarian cancer and scheduled for operation were prospectively studied using the murine monoclonal antibody OV-TL 3 F(ab’)2 labeled with Indium-111. After intravenous injection with 140 MBq of the radiolabeled antibody fragment a systematic quantitative analysis of the distribution of the radioimmunoconjugate was performed.
Tumor/tissue uptake ratios were 9.8 and higher for several background tissues (muscle, skin, omentum and blood) resulting in very informative images. Highest uptake was measured in liver tissue (11.5±5.1% ID/kg), being 3 times as high as the uptake in tumor tissue (3.9±1.0% ID/kg). Excretion of the radiolabel from the body was mainly in the urine, being 16.1% ID in 96 hr. But also excretion in feces measured over the same period of time was markedly high (3.1±1.9% ID), being in the same range as the mean total amount of uptake in tumor tissue in an individual patient.
For future imaging studies the problems encountered at image interpretation of urine, bowel and ascites activity can easily be solved. However the high disturbing uptake of Indium-111 in the liver may only be solved by chosing a different, by preference, non-metallic radionuclide.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Neit JP. Combination chemotherapy in the treatment of advanced ovarian carcinoma. Ph D Thesis, Utrecht, 1983, ICG Printing, Dordrecht.
Bast RC Jr, Klug TL, St. John E, et al. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med 309, 883–887, 1983.
Kenemans P, Bast RC, Yedema CA, Price MR, Hilgers J. CA 125 and polymorphic epithelial mucin as serum tumor markers. Cancer Rev 1988; 11–12:119–144.
Brenner DE, Shaff MI, Jones HW, Grosh WW, Greco FA, Burnett LS. Abdominopelvic computed tomography: evaluation in patients undergoing second-look laparotomy for ovarian carcinoma. Obstet Gynecol 1985; 65:715–719.
Epenetos AA, Mather S, Granowska M, et al. Targeting of iodine-123-labelled tumour-associated monoclonal antibodies to ovarian, breast, and gastrointestinal tumours. Lancet 1982; ii:999–1004.
Verheijen RHM, Massuger LFAG, Kenemans P, Haisma HJ, Epenetos AA. Polymorphic epithelial mucin and CAl25bearing glycoprotein as targets for imaging and therapy with monoclonal antibodies. Cancer Rev 1988; 11–12:145–172.
Massuger LFAG, Kenemans P, Claessens RAMJ, et al. Immunoscintigraphy of ovarian cancer with Indium-111labeled OV-TL 3 F(ab’)2 monoclonal antibody. J Nucl Med (accepted).
Poels LG, Peters D, Van Megen Y, et al. Monoclonal antibody against human ovarian tumor-associated antigens. J Natl Cancer Inst 1986; 76:781–791.
Boerman OC, van Niekerk CC, Makkink K, Hanselaar AGJM, Kenemans P, Poels LG. A comparative immunohistochemical study of four monoclonal antibodies directed against ovarian carcinoma associated antigens. Int J Gynecol Pathol (accepted).
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1990 Springer Science+Business Media Dordrecht
About this chapter
Cite this chapter
Massuger, L.F.A.G. et al. (1990). Pharmacokinetics and Tissue Distribution of Indium-111-Labeled OV-TL 3 F(ab’)2 in Ovarian Cancer Patients. In: Crommelin, D.J.A., Schellekens, H. (eds) From Clone to Clinic. Developments in Biotherapy, vol 1. Springer, Dordrecht. https://doi.org/10.1007/978-94-011-3780-5_10
Download citation
DOI: https://doi.org/10.1007/978-94-011-3780-5_10
Publisher Name: Springer, Dordrecht
Print ISBN: 978-94-010-5683-0
Online ISBN: 978-94-011-3780-5
eBook Packages: Springer Book Archive